CURRICULUM VITAE

Milhan Telatar, PhD, FACMG

Associate Clinical Professor and Director, Clinical Molecular Diagnostic Laboratory
Division of Molecular Pathology & Therapy Biomarkers
Department of Pathology, City of Hope National Medical Center
1500 E. Duarte Rd., Duarte, CA 91010
Office Phone: 626-218-9433
Email: mtelatar@coh.org
Date Prepared: May, 2022

I. EDUCATION

1990 Bogazici University, Istanbul, Turkey, Bachelor of Science, Biology.

1994 Bogazici University, Istanbul, Turkey, Doctor of Philosophy, Human Genetics.
Mentors: Asli Tolun, PhD, Bogazici University and Richard R. Gatti MD, UCLA.

II. POST GRADUATE EDUCATION AND TRAINING

1994- 1997 Postdoctoral Researcher, UCLA, Department of Pathology, Los Angeles, CA, USA.

1999- 2000 Fellow, Lymphoma Research Foundation of America.

1997- 1999 Fellow, UCLA, Intercampus Medical Genetics Program, Los Angeles, CA, USA.

III. PROFESSIONAL EXPERIENCE, POSITIONS & EMPLOYMENT

2013-Present Director, Clinical Molecular Diagnostic Laboratory, Department of Pathology, City of Hope.

2005-2013 Scientific Director, Molecular Genetics, Specialty Laboratories/Quest Diagnostics.

1997-2005 Co-Director, Orphan Disease Testing Lab, UCLA, Department of Pathology, UCLA.

Other Professional Activities

Affiliations

- American Society of Human Genetics (ASHG).
- Association for Molecular Pathology (AMP).
- American College of Medical Genetics and Genomics (ACMGG).

Certifications

- Fellow of American College of Medical Genetics and Genomics, 1999.
- Diplomate of American Board of Medical Genetics and Genomics, 1999, 2010, 2020.

Licences

- Clinical Genetic Molecular Biologist, State of California, DRN24, 2004.
- Certificate of Qualification, New York State Department of Health, TELAM1, 2005.
  - Genetic Testing-Limited to Molecular.
  - Oncology-Molecular and Cellular Markers .
  - Histocompatibility-Limited to HLA typing.
  - Virology-Limited to Molecular.

IV. NATIONAL HONORS, SCHOLARSHIPS AND AWARDS HONORS AND AWARDS

2011 Recognition of Excellence, Quest Diagnostics.

1994 PhD Thesis Award, Bogazici University Research Fund.

V. GRANTS/RESEARCH SUPPORT

COMPLETED GRANTS/RESEARCH SUPPORT

Sept 2002 - Aug 2006 Grant Number: DC005663-R01
Sponsor: NIH-NIDCD
Title: Connexin 26 Testing in Infants
Annual Direct Support: $343,125
Role on grant: Scientist

July 1999 - July 2000 Sponsor: Lymphoma Research Foundation of America
Title: Assessment of Molecular Emission and Stem Cell Purity in Follicular Lymphoma.
Annual Direct Support: $10,000
Role on grant: Principal Investigator

Oct 1999 - Jan 2006 Grant Number: CA76513-R01
Sponsor: NIH-NCI
Title: Risk of Cancer in A-T Families
Annual Direct Support: $1,210,713
Role on grant: Co-Investigator

Jan 1998 - Jan 2006 Grant Number: NS35322-R01
Sponsor: NIH-NINDS
Title: Preclinical Studies of Ataxia Telangiectasia
Annual Direct Support: $1,800,000
Role on grant: Co-Investigator

Mar 1987- Mar 1996 Grant Number: 87ER60548
Sponsor: The US Department of Energy
Title: Human Gene for Radiation Hypersensitivity
Annual Direct Support: $2,627,000
Role on grant: Scientist, PhD Student

VI. INVITED SEMINARS/LECTURES/FORUMS

Jan 2019 Southern California Regional Molecular and Cytogenetics Meeting at City of Hope
- Case Review

Apr 2018 City of Hope Managers' Forum
- CMDL's impacts on patient, and the future of molecular testing at City of Hope

Apr 2015 City of Hope Medical Group
- CMDL Overview

VII. TEACHING/EDUCATION/EDUCATIONAL ACTIVITIES

Ph.D. Dissertation Committee Service
Name of student: None
Description of studies/thesis title
Relationship (committee member, etc.)
Date(s)

Graduate Students (Trained)
Name of student: Helen Chun
Degree: PhD
Description of studies: Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations
Date of graduation: 2004
Current position: Associate Professor at California State University, Dominguez Hills

Postdoctoral Fellows (Trained)
Name of student: None
Description of training
Date/s of training
Current Position

Other Research Mentoring Activities/Committees (e.g. Eugene and Ruth Roberts Summer Academy)

Clinical Genetic Molecular Biologist Scientist (CGMBS) Training Program at City of Hope

2014-Present	Curriculum development for the CGMBS Program at City of Hope.
2015-2016	Teaching, training, and mentoring: Carrie Louie PhD.
2015-2016	Teaching, training, and mentoring: Hao Hong PhD
2017-2018	Teaching, training, and mentoring: Christina Wada.
2018-2019	Teaching, training, and mentoring: Drew Walker.
2019-2020	Teaching, training, and mentoring: Heather Cox.
2021-Present	Teaching, training, and mentoring: Marianne Dogoldogol.

Multidisciplinary Genomic Tumor Board, Department of Pathology, City of Hope

2016-Present	Training, and mentoring the CMDL Molecular Data Curators in analyzing and interpretation of the molecular results.
2016	Teaching, training, and mentoring: Ching-Ying (Jenny) Kuo PhD.
2017	Teaching, training, and mentoring: Hooi Yew PhD.
2017	Teaching, training, and mentoring: Hsiao-Wei Chen.
2021	Teaching, training, and mentoring: Mariel Gust.

CMDL, New Test Development Section, Department of Pathology, City of Hope

2013-Present	Teaching, training and mentoring CMDL Development Specialists in designing and validating molecular assay.
2014	Mentored scientists: Hao Hong PhD.
2015	Mentored scientists: Maria Cuellar.
2017	Mentored scientists: Vanina Tomasian, MS.
2020	Mentored scientists: Nahid Haghighi.

VIII. SERVICE TO INSTITUTION

Administrative and Operational Service

2013-Present Director, Clinical Molecular Diagnostic Lab, Department of Pathology, City of Hope

- Establishes, direct, supervises, and monitors technical, operational, and administrative activities within department, including new assay development, fiscal supervision, the scope and nature of QC/QA/QI procedures, and supervision of personnel.
- Ensures the smooth operation of the department and monitors department to ensure compliance with all applicable local, state, and Federal licensing regulations.
- Writes, reviews, and approves policies, protocols, and validation reports.
- Oversees the Clinical Genetic Molecular Biologist Scientist (CGMBS) training program at City of Hope. The training program is approved by California Department of Public Health to train qualified individuals for eligibility and licensure as CGMBS, and is held jointly with California State University at Los Angeles.

2005-2013 Scientific Director, Molecular Genetics Laboratory, Specialty Labs/Quest Diagnostics

- Established, directed, supervised, and monitored technical, operational, and administrative activities within department, including fiscal supervision, the scope and nature of QC/QA/QI procedures, and supervision of personnel.
- Ensured the smooth operation of the department through and monitors department to ensure compliance with all applicable local, state, and Federal licensing regulations.
- Wrote, reviewed, and approved policies, protocols, and validation reports.

1997-2005 Co-Director, Orphan Disease Testing Lab, Department of Pathology, UCLA

- Established a CLIA-certified and CAP-accredited lab.
- Wrote QA/QC policies and procedures.
- Wrote SOPs and validation reports.
- Developed and implemented testing platforms.

IX. SERVICE TO PROFESSION

2015-Present Multidisciplinary Genomic Tumor Board, City of Hope.
2017-Present Pathology Admin Leadership.
2015-2017 Clinical Lab Operations Committee, City of Hope.
2008-2013 Hematology/Oncology Subspecialty Committee, Quest Diagnostics.
2008-2013 Molecular QC Best Practice Team, Quest Diagnostics.
2007-2013 Genetics Subspecialty Committee, Quest Diagnostics.
2007-2013 Genetics Best Practice Team, Quest Diagnostics.
2007-2010 Hematopathology Resource Committee, Quest Diagnostics.
2005-2007 Hematopathology Resource Committee, Ameripath.

X. PUBLICATIONS

Publications (peer-reviewed) 37 Total

1. AldossI, Yang D, Tomasian V, et al "Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL" 2021, Haematologica, Submitted.

2. Wong KS, Dong F, **Telatar M**, et al. Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome. Thyroid. Published online January 19, 2021: thy.2020.0668.

3. Afkhami M, Schmolze D, Yost SE, et al. Mutation and immune profiling of metaplastic breast cancer: Correlation with survival. PLoS ONE. 2019;14(11):e0224726.

4. Salhotra A, Afkhami M, Yang D, et al. Allogeneic hematopoietic cell transplantation outcomes in patients carrying isocitrate dehydrogenase mutations. Clinical Lymphoma Myeloma and Leukemia. 2019;19(7):e400-e405.

5. Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, **Telatar M**, et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. Haematologica. 2017;102(12):2030-2038.

6. Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, **Telatar M**, et al. Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of mutational status. Haematologica. 2017;102(12):2030-2038.

7. Cho M, Akiba C, Lau C, Smith D, **Telatar M** et al. Impact of RAS and BRAF mutations on carcinoembryonic antigen production and pattern of colorectal metastases. World J Gastrointest Oncol. 2016;8(1):128-35.

8. M. Afkhami, V. Sharma, M. Cuellar, M. D'Apuzzo, B. Badie, J. Portnow, R. Pillai, P. A. Aoun, **M. Telatar** "Detection of MGMT Promoter Methylation in Malignant Gliomas" J Clin Oncol 34, 2016 (suppl; abstr e23131).

9. Cho M, Akiba C, Lau C, Smith D, **Telatar M**, et al. "Impact of RAS and BRAF mutations on CEA production and pattern of colorectal metastases" World J Gastrointest Oncol. 8(1), pp 128-35, 2016.

10. Pratt VM, Zehnbauer B, Wilson JA, Baak R, Babic N, Bettinotti M, Buller A, Butz K, Campbell M, Civalier C, El-Badry A, Farkas DH, Lyon E, Mandal S, McKinney J, Muralidharan K, Noll L, Sander T, Shabbeer J, Smith C, **Telatar M,** et. al. "Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project" J Mol Diagn. 12(6), pp 835-46. 2010.

11. Barker SD, Bale S, Booker J, Buller A, Das S, Friedman K, Godwin AK, Grody WW, Highsmith E, Kant JA, Lyon E, Mao R, Monaghan KG, Payne DA, Pratt VM, Schrijver I, Shrimpton AE, Spector E, **Telatar M**, et al. "Development and characterization of reference materials for MTHFR, SERPINA1, RET, BRCA1, and BRCA2 genetic testing" J Mol Diagn. 11(6), pp: 553-61. 2009.

12. Schimmenti LA, Martinez A, **Telatar M**, et al. Infant hearing loss and connexin testing in a diverse population. Genet Med. 2008;10(7):517-524.

13. Jarvis, M., Iyer, R. K., Williams, LO., Noll, WW., Thomas, T., **Telatar, M**. and Grody, WW. " A Novel Method for Creating Artificial Mutant Samples for Performance Evaluation and Quality Control in Clinical Molecular Genetics" J Mol Diagn 7(2), pp 247-251, 2005.

14. Schimmenti LA, Martinez A, Fox M, Crandall B, Shapiro N, **Telatar M**, Sininger Y, Grody WW, Palmer CG. "Genetic testing as part of the early hearing detection and intervention (EHDI) process" Genet Med 6(6), pp 521-525, 2004.

15. Palmer, CG., Martinez, A., Fox, M., Crandall, B., Shapiro, N, **Telatar, M**, Sininger, Y., Grody, WW., Schimmenti, LA." Genetic Testing and the Early Hearing Detection and Intervention Process" The Volta Review 103 (4), pp 371-390, 2003.

16. Grody, W.W., Jiang Z, **Telatar M**, and Galvin N. "Multiplex SNP analysis: Screening for factor V R506Q (Leiden) mutations and clinical implication". Am. Biotechnol. Lab. 21(2): 34-38, 2003.

17. Emmanouilides C, Lill M, **Telatar M**, Rosenfelt F, Grody W, Territo M, Rosen P. "Mitoxantrone/Ifosfamide/Etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma" Clin Lymphoma 2002 Vol. 3, pp 111-6, 2002.

18. **Telatar, M**., Grody, W.W., Emmanouilides C. "Detection of bcl-2/IgH Rearrangements by Quantitative-Competitive PCR and Capillary Electrophoresis" Molec. Diagn. Vol. 6, pp 161-168, 2001.

19. Emmanouilides C., Rosen, P., **Telatar, M**., Malone, R., Bosserman, L., Menco, H., Patel, R., Barstis, J., Grody, W.W. "Excellent Tolerance of Rituximab When Given After Mitoxantrone/Cyclophosphamide: An Effective and Safe Combination for Indolent Non-Hodgkin's Lymphoma" Clinical Lymphoma Vol. 1, pp 146-151, 2000.

20. Teraoka, S.N., **Telatar, M**., Becker-Catania, S., Liang, T., Onengut, S., Tolun, A., Chessa, L., Sanal, O., Bernatowska, E., Gatti, R.A., Concannon, P. "Splicing defects in the ataxia-telangiectasia gene, ATM: underlying mutations and consequences" Am. J. Hum. Genet. Vol 64, pp 1617-31, 1999.

21. Castellvi-Bel, S., Sheikhavandi, S., **Telatar**, M., Tai, L-Q., Hwang, M., Wang, Z., Yang, Z., Cheng, R., Gatti R.A. "New mutations, polymorphisms, and rare variants in the ATM gene detected by a novel SSCP strategy" Hum. Mutat., Vol 14, pp 156-62, 1999.

22. **Telatar, M.,** Wang, Z., Castellvi-Bel, S., Tai, L-Q., Sheikhavandi, S., Regueiro, J.R., Porras, O., Gatti, R.A. "A Model for ATM Heterozygote Identification in a Large Population: Four Founder Effect ATM Mutations Identify Most of Costa Rica Patients with Ataxia-Telangiectasia" Molecular Genetics and Metabolism, Vol 64, pp 36-43, 1998.

23. Laake, K., **Telatar, M**., Geitvik, G.A., Hansen, R.O., Heiberg, A., Andersen, A.M., Gatti, R.A. and Borresen-Dale, A.L. "Identical Mutation in 55% of the ATM alleles in 11 Norwegian AT Families; Evidence for a Founder Effect," Eur. J. Hum. Genet., Vol 6, pp 235-244, 1998.

24. **Telatar, M**., Teraoka, S., Wang, Z, Chun, H.H., Liang, T., Castellvi-Bel, S., Udar, N., Borresen-Dale, A.L., Chessa, L., Bernatowska-Matuszkiewick, E., Porras, O., Watanabe, M., Junker, A., Concannon, P., Gatti, R.A. " Ataxia-Telangiectasia: Identification and Detection of Founder-Effect Mutations in the ATM Gene in Ethnic Populations," Amer. J. of Hum. Genet., Vol 62, pp 86-97, 1998.

25. Geschwind, D.H., Perlman, S., Grody, W.W., Telatar, M., Montermini, L., Pandolfo, M., Gatti, R.A. "Friedreich's Ataxia GAA Repeat Expansion in Patients with Recessive or Sporadic Ataxia," Neurology, Vol 49, pp 1004-1009, 1997.

26. Chen, X., Yang, L., Udar, N., Liang, T., Uhrhammer, N., Xu, S., Bay, J.O., Wang, Z., Dandakar, S.,Chiplunkar, S., Klisak, I., **Telatar, M.,** Yang, H., Concannon, P., Gatti, R.A. "CAND3: a Ubiquitously-Expressed Gene Immediately Adjacent and in opposite Transcriptional Orientation to the ATM Gene at 11q23.1," Mammalian Genome, Vol 8, pp 129-133, 1997.

27. **Telatar, M**., Wang, Z., Udar, N., et al. "Ataxia-Telangiectasia: Mutations in cDNA Detected by Protein Truncation Screening," Amer. J. of Hum. Genet., Vol 59, pp 40-44, 1996.

28. Kavaslar, G.N., **Telatar, M**., Serdaroglu, P., Deymeer, F., Ozdemir, C., and Tolun, A., "Identification of a One Base Pair Deletion in Exon 6 of the Dystrophin Gene," Hum. Mut., Vol 6, pp 85-86, 1995.

29. Lange, E., Borresen, A-L., Chen, X., Chessa, L., Chiplunkar, S., Concannon, P., Dandekar, S., Gerken, S., Lange, K., Liang, T., McConville, C., Polakow, J., Porras, O., Rotman, G., Sanal, O., Sheikhavandi, S., Shiloh, Y., Sobel, E., Taylor, M., **Telatar, M**., et al. "Localization of an Ataxia-Telangiectasia Gene to a ~500 Kb Interval on Chromosome 11q23.1: Linkage Analysis of 176 Families in an International Consortium," Amer J of Hum Genet., Vol 57, pp 112-119, 1995.

30. **Telatar**, M., Lange, E., Uhrhammer, N., and Gatti, R. A., "New Localization of NCAM, Proximal to DRD2 at Chromosome 11q23," Mammalian Genome, Vol 6, pp 59-60, 1995.

31. Gatti, R.A., Lange, E., Rotman, G., Chen, X., Uhrhammer, N., Liang, T.,Chiplunker, S., Yang, L., Udar, N., Dandekar, S., Sheikhavandi, S., Wang, Z., Yang, H-M., Polikow, J., Elashoff, M., **Telatar, M**., et al. "Genetic Haplotyping of Ataxia-Telangiectasia Families Localizes the Major Gene to a ~850 Kb Region on Chromosome 11q23.1," International J Radiation Biology Vol 66, pp S57-S62, 1994.

32. Angelicheava, D., Boteva, K., Jordanova, A., Savov, A., Kufardjieva, A., Tolun, A., **Telatar, M**., et al. "Cystic Fibrosis Patients from the Black Sea Region: The 1677delTA Mutation," Hum. Mut., Vol 3, pp 353-357, 1994.

33. **Telatar, M**., Concannon, P., and Tolun, A., "Dinucleotide Repeat Polymorphism at 11q23," Hum. Genet., Vol 94, pp 109, 1994.

34. **Telatar, M**., Concannon, P., and Tolun, A., "Dinucleotide Repeat Polymorphism at the NCAM locus," Hum. Molecular Genet., Vol 3, pp 842, 1994.

35. Sanal, O., Lange, E., **Telatar, M.,** Sobel, E., Salazar-Novak, J., Ersoy, F., Morrison, A., Concannon, P., Tolun, A., and Gatti, R. A., "Ataxia-Telangiectasia: Linkage Analysis of Chromosome 11q22-23 Markers in Turkish Families," FASEB J., Vol 6, pp 2848-2852, 1992.

36. Battaloglu, E., **Telatar, M**., Deymeer, F., et al., "Carrier Detection by DNA Analysis in Duchenne Muscular Dystrophy Families," The Turkish Journal of Pediatrics, Vol 34, pp 79-92, 1992.

37. Battaloglu, E., **Telatar, M**., Deymeer, F., Serdaroglu, P., Kuseyri, F., Ozdemir, C., Yuksel-Apak, M., and Tolun, A., "DNA Analysis in Turkish Duchenne/Becker Muscular Dystrophy Families," Hum. Genet., Vol 89, pp 635-639, 1992.

Publications (review articles) 1 Total

1) **Telatar, M**., Grody, W.W. "Molecular genetic testing for Familial Mediterranean Fever" Mol. Genet. Metab. Vol 71, pp 256-60, 2000.

Book Chapters 1 Total

1. Grody WW, Seligson D, **Telatar M,** "Carrier Screening" Emery and Rimoin's Principles and Practices of Medical Genetics 4th Edition, Edited by Rimoin D. L., Connor, J. M., Pyeritz, R. E., Korf, B., Churchill Livingstone, 2002.

Published Abstracts 23 Total

1. **Telatar M,** Cuellar MT, Louie C, Afkhami M, Pillai R, Gu D, Chu P, Aoun P. Analytical Validation of an NGS-Based Diagnostic Test to Detect Common Fusions in Solid Tumors from Formalin-Fixed, Paraffin-Embedded (FFPE) Tissues. J Mol Diagn. 2015;17(6):830.

2. Hong H, **Telatar D**, Pillai RK, Louie C, Mehta V, Gu D, Fong C, Afkhami M, Aoun P. Clinical Validation of A 11-Gene Next-Generation Sequencing Panel for Hereditary Colon Cancer. J Mol Diagn. 2015;17(6):763.

3. Hong H, **Telatar M,** Pillai RK, Louie C, Mehta V, Gu D, Fong C, Afkhami M, Aoun P. Validation of a 22-Gene Next-Generation Sequencing Panel for Inherited Connective Tissue Disorders for Clinical Use. J Mol Diagn. 2015;17(6):764.

4. **Telatar M**, Hong H, Pillai RK, Louie C, Mehta V, Gu D, Fong C, Weitzel J, Afkhami M, Aoun P. Validation of A 28-Gene Next-Generation Sequencing Panel for Hereditary Risk of Breast, Ovarian and Endometrial Cancers for Clinical Use. J Mol Diagn. 2015;17(6):763.

5. Cuallar MT, **Telatar M,** Louie C, Mehta V, Fong C, Chu P, Afkhami M, Aoun P. Validation of the Prosigna Breast Cancer Prognostic Gene Signature in the Clinical Lab. J Mol Diagn. 2015;17(6):831.

6. Afkhami M, Sharma V, Cuellar M, D'Apuzzo M, Badie B, Portnow J, Pillai RK, Aoun PA, **Telatar M.** Detection of MGMT promoter methylation in malignant gliomas. J Clin Oncol. 2016;34(15):e23131.

7. **Telatar M,** Aoun P, Cuellar M, Chu P, Twardowski P, Salehian B, Pillai R, Afkhami M. A Next-Generation Sequencing (NGS) 53-Gene Fusion Assay Identifies Known, Rare, and Novel Fusions in Solid Tumors. J Mol Diagn. 2016;18(6):1029.

8. Afkhami M, **Telatar M,** Cuellar M, Maghami E, Salehian B. A Novel Fusion in Anaplastic Thyroid Carcinoma Detected Using an Extended Next Generation Sequencing Fusion Assay. Thyroid. 2016;26:Short Call Poster 71.

9. Cho MT, Goldstein L, Akiba C, Lau SC, **Telatar M,** Afkhami M, Sentovich S, Melstrom K, Lim D, Chao J, Chung VM, Fakih M. RAS mutational status and CEA production at initial presentation in metastatic colorectal cancer. J Clin Oncol. 2016;34(4):Meeting Abstract: 542.

10. Nakamura R, Aldoss I, Pham A, Li SM, Gendzekhadze K, Afkhami M, **Telatar M,** Hong H, Padeganeh A, Bedell V, Cao T, Khaled S, Al Malki MM, Salhotra A, Ali H, Aribi A, Palmer JM, Aoun P, Spielberger R, Stein AS, Snyder DS, O'Donnell MR, Murata-Collins J, Senitzer D, Weisenburger DD, Forman SJ, Pullarkat V, Marcucci G, Pillai R. Favorable Impact of Allogeneic Stem Cell Transplantation in Patients with Therapy-Related Myelodysplasia Regardless of TP53 Mutational Status. Blood. 2017;130:4248.

11. Afkhami M, Melstrom L, Nguyen K, Terrones AB, Pillai R, Gu DQ, **Telatar M,** Aoun PA. Non-V600E BRAF Mutations Are More Common in Cutaneous Melanomas of Head and Neck and Upper Extremity. Lab Invest. 2017;97:126A.

12. Siaghani P, Yang LX, Zhao L, **Telatar M,** Cuellar M, Himchak E, Yin HH, Weisenburger DD, Aoun P, Afkhami M, Pillai RK. High Sensitivity Detection of IDH1/2 Mutations for Assessment of Minimal Residual Disease. Lab Invest. 2018;98:821.

13. Cloe A, Pillai R, **Telatar M**, Yew H, Weisenburger DD, Pullarkat V, Aldoss I, Kuo CY, Aoun P, Afkhami M. Novel Fusion of TCF3-MEF2B in BCR-ABL Negative B-Lymphoblastic Leukemia. Lab Invest. 2018;98:508-509.

14. Ally F, Jariwala A, Aoun PA, **Telatar M**, Pillai RK, Ali H, Snyder D, Louie C, Afkhami M. Chronic myelomonocytic leukemia genomic signature correlates with the degree of bone marrow fibrosis: A single-institutional retrospective study. J Clin Oncol. 2020;38(15):Meeting Abstract: 7559.

15. Chen H, **Telatar M**, Louie C, D'Apuzzo M, Portnow J, Badie B, Arvanitis L, Yew H, Gu D, Pillai R, Aoun P, Arias-Stella J, Afkhami M. Co-occurrence of PTEN and TERT Mutations Predicts Poor Prognosis in Glioblastomas. J Mol Diagn. 2020;22(11):S77.

16. **Telatar M,** Louie C, Chen HW, Pillai R, Arias-Stella J, Slavin T, Yew H, Margolin K, Salgia R, Aoun P, Afkhami M. Identification of Potentially Actionable Germline Variants in NGS Testing of Solid Tumors. J Mol Diagn. 2020;22(5):S67-S68.

17. Nguyen H, Mallick J, Aoun P, Pillai R, **Telatar M,** Yew H, Louie C, Wei H, Gu D, Jariwala A, Aldoss I, Salhotra A, Ali H, Snyder D, Marcucci G, Stein A, Nakamura R, Afkhami M. Mutational Profiles of Persistent versus Relapsed/Recurrent Acute Myeloid Leukemia: A Two-and-a-Half-Year Experience of a Cancer Center. J Mol Diagn. 2020;22(5):S25-S26.

18. Wong K, Dong F, Barletta J, Afkhami M, **Telatar M.** Papillary Thyroid Carcinoma with High Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome. Lab Invest. 2020;100(SUPPL 1):604-605.

19. Arvanitis L, Chen HW, Louie C, D'Apuzzo M, Gu DQ, Yew H, Portnow J, Badie B, Pillai R, Aoun P, **Telatar M,** Afkhami M. PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma. Lab Invest. 2020;100(SUPPL 1):1600.

20. Arvanitis L, Chen HW, Louie C, D'Apuzzo M, Gu D, Yew H, Portnow J, Badie B, Pillai R, Aoun P, **Telatar M,** Afkhami M. PD-L1 (22C3) Expression in Primary and Recurrent Glioblastoma. Mod Pathol. 2020;33(SUPPL 2):1600.

21. Aldoss I, Yang D, Gu Z, Tomazian V, Mokhtari S, Jackson R, **Telatar M,** Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz AS, Aoun P, Gu D, Snyder DS, Stewart FM, Curtin PT, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat VA, Nakamura R, Afkhami

M. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting & Exposition: American Society of Hematology; 2021.

22. Aldoss I, Afkhami M, Yang D, Mokhtari S, Tomasian V, **Telatar M,** Yew H, Al Malki MM, Salhotra A, Khaled SK. Outcomes of Allogeneic Hematopoietic Cell Transplantation (AlloHCT) in Adults with Philadelphia-like (Ph-like) Acute Lymphoblastic Leukemia (ALL). Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR: TCT Meetings; 2021.

23. Aldoss I, Yang D, Gu Z, Tomazian V, Mokhtari S, Jackson R, **Telatar M**, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz AS, Aoun P, Gu D, Snyder DS, Stewart FM, Curtin PT, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat VA, Nakamura R, Afkhami M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Adults with Ph-like ALL. Blood. 2021;138(Supplement 1):3955.

XI. PATENTS, INVENTIONS & COPYRIGHTS

Technologies Licensed

1. 2019 #5.995.279 Gatti et al Ataxia-telangiectasia: mutations in the ATM gene.
2. 2005 #6,951,724 Gatti et al Methods for detection of ATM mutations.